Image by Wyman Meinzer

Pipeline

Reata's technologies and development programs have yielded a deep pipeline of preclinical- and clinical-stage drug candidates for a broad array of indications where there is significant unmet need.

READ MORE »

News

04.10.2015 - Reata Pharmaceuticals' bardoxolone methyl receives FDA Orphan Drug Designation in Pulmonary Arterial Hypertension

03.03.2015 - Reata's Chief Medical Officer, Dr. Colin Meyer, Spoke with FARA's Kyle Bryant about Reata and the MOXIe Study of RTA 408 on Friedreich's Ataxia

01.29.2015Reata Enrolls First Patient in the MOXIe Study, a Phase 2/3 Study Examining RTA 408 in Friedreich's Ataxia Patients

READ MORE »

In-licensing

Reata is actively seeking in-licensing and collaborative development opportunities for novel therapeutics to supplement our internal discovery efforts.

READ MORE »